Eisai sales and marketing update

Eisai will establish a new sales and marketing operation in Moscow, Russia, and plans to launch breast cancer drug Halaven eribulin as its first product this quarter. The pharma then expects to launch its epilepsy portfolio, which includes Zonegran zonisamide, an anticonvulsant that blocks sodium (Na) and calcium (Ca) channels, and Exalief eslicarbazepine acetate, a sodium channel blocker, as adjunctive therapies for partial seizures in adults with epilepsy. Eisai could not be reached for details. ...